News | November 01, 2023
Pfizer posts Q3 loss as Covid-19 revenues shrink
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Proposed combination enhances Pfizer’s position as a leading company in oncology
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
Subscribe To Our Newsletter & Stay Updated
